Skip to main content
    R

    Rein Therapeutics Inc (RNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.55
    -0.01 (-1.41%)

    Market Cap: $47.63M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Rein Therapeutics Inc (RNTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Rein Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$49.87M, operating cash flow was -$19.36M and free cash flow was -$19.36M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$5.54M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $50.63M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$11.03M$14.25M$3.99M$17.97M$17.01M$11.17M$17.66M$18.45M$14.24M$10.28M
    Operating income-$50.63M-$65.11M-$16.28M-$27.65M-$26.61M-$20.50M-$29.96M-$31.90M-$23.01M-$18.17M
    Net income-$49.87M-$62.88M-$15.73M-$27.33M-$26.16M-$21.16M-$29.37M-$31.55M-$22.60M-$18.12M
    EBITDA-$50.58M-$64.36M-$15.58M-$27.37M-$25.80MN/A-$29.45MN/AN/A-$17.94M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$7.00M-$6.08M-$5.23M-$32.66M-$5.49M-$6.87M-$5.61M-$42.80M-$6.07M-$9.04M-$7.21M-$7.29M
    Net income-$5.54M-$6.38M-$5.84M-$31.97M-$5.58M-$6.82M-$5.50M-$40.98M-$5.85M-$8.94M-$7.11M-$7.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $3.21M. Shareholder equity was negative, at -$28.09M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$24.16M$62.19M$106.01M$22.01M$48.48M$16.34M$26.47M$30.31M$52.69M$22.02M
    Current assets$4.33M$13.66M$18.27M$21.87M$48.18M$16.33M$19.55M$21.77M$51.84M$21.07M
    Cash and equivalents$3.21M$12.87M$17.31M$5.19M$3.60M$7.05M$5.31M$10.63M$11.86M$20.71M
    Total liabilities$7.24M$7.80M$7.71M$3.38M$4.58M$4.18M$10.43M$10.71M$4.89M$4.08M
    Short-term debt$0N/A$48.00K$33.00K$93.00K$168.00K$446.00KN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$219.00KN/AN/AN/AN/A
    Shareholder equity-$28.09M$9.39M$6.89M$18.62M$43.90M$12.16M$16.05M$19.60M$47.80M-$111.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$59.43M$65.97M$26.29M$24.16M$53.71M$57.48M$57.63M$62.19M$104.22M$109.40M$99.19M$106.01M
    Total liabilities$6.66M$10.77M$14.70M$7.24M$7.52M$9.47M$7.75M$7.80M$8.98M$8.38M$7.86M$99.12M
    Cash and equivalents$943.00K$8.54M$4.45M$3.21M$4.05M$5.72M$7.43M$12.87M$17.65M$21.92M$12.04M$17.31M
    Shareholder equity$7.77M$10.20M-$33.41M$16.92M$1.19M$3.01M$4.87M$54.39M$50.23M$56.02M$44.75M$6.89M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$19.36M-$22.29M-$19.81M-$24.86M-$23.75M-$20.48M-$26.47M-$27.93M-$20.53M-$15.01M
    Capital expenditures$0$0$0$0$157.00K$5.00K$151.00K$4.42M$142.00K$0
    Free cash flow-$19.36M-$22.29M-$19.81M-$24.86M-$23.91M-$20.48M-$26.63M-$32.35M-$20.67M-$15.01M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/A$2.30M$180.00K
    Investing cash flow$0$0$16.20M$26.46M-$35.92M$6.41M-$2.81M$24.69M-$38.91M-$25.00K
    Financing cash flow$9.76M$17.82M$15.79M$0$55.66M$15.80M$23.96M$2.52M$50.59M$31.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.27M-$8.64M-$3.42M-$3.22M-$3.55M-$6.42M-$6.17M-$4.81M-$3.82M-$8.39M-$5.27M-$10.39M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$10.39M
    Free cash flowN/AN/A-$3.42M-$3.22M-$3.55M-$6.42M-$6.17M-$4.81M-$3.82M-$8.39M-$5.27M-$20.78M
    Last 12 quarters

    Frequently Asked Questions About RNTX

    What is Rein Therapeutics' annual revenue?

    Rein Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Rein Therapeutics profitable?

    No. Rein Therapeutics reported net income of -$49.87M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does RNTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$19.36M minus capital expenditures of $0 produced free cash flow of -$19.36M.

    How much debt does Rein Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $3.21M.